Contraindicated. Coadministration of doravirine with a solid CYP3A inducer may lessen doravirine plasma concentrations and/or effects. Prospective for lack of virologic response and doable resistance to doravirine.
pentobarbital will minimize the extent or effect of armodafinil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Mysterious.
pentobarbital will reduce the extent or impact of clarithromycin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unknown.
pentobarbital will lessen the extent or outcome of finasteride by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Not known.
pentobarbital will minimize the extent or result of isradipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unidentified.
pentobarbital will decrease the extent or impact of ethinylestradiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. The efficacy of hormonal contraceptives may very well be minimized. Utilization of a nonhormonal contraceptive is recommended.
pentobarbital and daridorexant both equally maximize sedation. Modify Therapy/Watch Carefully. Coadministration raises threat of CNS depression, which can cause additive impairment of psychomotor general performance and bring about daytime impairment.
pentobarbital will reduce more info the level or influence of donepezil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Mysterious.
pentobarbital will minimize the level or outcome of zonisamide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.
Elderly or debilitated patients may respond to barbiturates with marked depression, enjoyment, and confusion; in a few people, barbiturates consistently make enjoyment rather then depression
pentobarbital will decrease the extent or outcome of alfentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unidentified.
pentobarbital will lessen the level or influence of fruquintinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, carry on to administer fruquintinib at encouraged dosage.
Coadministration of zuranolone with other CNS depressants may increase impairment of psychomotor performance or CNS depressant effects. If unavoidable, take into account dose reduction. .
pentobarbital will minimize the extent or influence of voriconazole by impacting hepatic enzyme CYP2C9/ten metabolism. Small/Significance Unknown.